The fund’s investment objective is to achieve capital growth for investors through investment in companies that have suffered a severe setback. The fund invests primarily in UK quoted shares. The investments are selected from those companies that have suffered a severe setback in terms of profits or share prices, but where the management and the prospects are believed to be good. Investment will be in directly held transferable securities. The fund may also invest in collective investment schemes, derivatives, warrants and money market instruments.
Name | % Net Assets |
---|---|
AstraZeneca | 5.6% |
Royal Bank of Scotland Group | 4.7% |
Rentokil Initial | 4.2% |
Morrison Supermarkets | 3.8% |
Barclays | 3.6% |
Lloyds Banking Group | 3.3% |
Vodafone Group | 3.2% |
Dixons Retail | 3.0% |
Resolution | 2.9% |
GlaxoSmithKline | 2.9% |
Key | % Net Assets |
---|---|
AstraZeneca | 5.6% |
Royal Bank of Scotland Group | 4.7% |
Rentokil Initial | 4.2% |
Morrison Supermarkets | 3.8% |
Other | 81.7% |
Date | 21-Nov-2024 |
---|---|
NAV | 28,350.00p |
Currency | GBP |
Change | -30.00p |
% | -0.11% |
YTD change | 1,110.00p |
YTD % | 4.07% |
Fund Inception | 05/05/1970 |
---|---|
Fund Manager | Kevin Murphy / Nick Kirrage |
TER | 1.52 (15-Jul-2012) |
Minimum Investment | |
---|---|
Initial | £1000 |
Additional | n/a |
Savings | £50 |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | 0.16 |
You are here: research